Press Releases< /span>
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 4, 2018
Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that pharmaceutical industry commercial executive, Michael Milloy, has joined the Company in the position of Vice...
-
Nov 7, 2018
Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three and nine months ended September 30th, 2018. Unless otherwise...
-
Oct 24, 2018
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the details of its Q3 2018 financial results conference call on Wednesday, November 7, 2018. The call will be...
-
Oct 24, 2018
Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Canadian launch of Brinavess® (vernakalant hydrochloride) for the rapid conversion of recent onset atrial fibrillation ("AF"), (an...
-
Sep 18, 2018
Transaction broadens Cipher's Canadian portfolio providing entry into rapidly growing market MISSISSAUGA,ON, Sept. 18, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has...
-
Sep 10, 2018
Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it received Health Canada approval of Xydalba™ (dalbavancin hydrochloride), the first and only one-dose treatment option for acute bacterial...
-
Aug 10, 2018
Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and six months ended June 30, 2018. Unless otherwise noted,...
-
Jul 30, 2018
Agreement expanded to include a portfolio of novel isotretinoin products New portfolio royalty extends through December 2024 MISSISSAUGA, ON, July 30, 2018 /CNW/ - Cipher Pharmaceuticals Inc....
-
Jul 23, 2018
Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q2 2018 financial results conference call on Friday, August 10, 2018. The call will be hosted...
-
Jun 6, 2018
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that pharmaceutical industry medical executive, Dr. Diane Gajewczyk, has joined the Company in the position of...
-
May 16, 2018
Effective May 15, 2018, the previously announced acquisition by Cipher Pharmaceuticals Inc. ("Cipher") of the Canadian business portfolio of Cardiome Pharma Corp. ("Cardiome") was completed by way...
-
May 15, 2018
Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has completed its previously announced strategic acquisition of the Canadian business portfolio of Cardiome Pharma Corp. (originally...
-
May 11, 2018
Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced today the voting results for the election of directors at its...
-
May 10, 2018
Company announces four transactions year to date adding revenue diversification and growth avenues in new therapeutic categories MISSISSAUGA, ON, May 10, 2018 /CNW/ - Cipher Pharmaceuticals Inc....
-
May 1, 2018
Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2018 financial results conference call and Annual and Special Meeting of shareholders on...
-
Apr 26, 2018
Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that experienced healthcare executive Dr. Laurence Terrisse-Rulleau is being proposed for election to Cipher's...
-
Apr 24, 2018
Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Robert Tessarolo, President and Chief Executive Officer, will present at the 2018 Bloom Burton & Co....
-
Apr 23, 2018
Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today provided a strategic and operational update and preliminary revenue results for the three months ended March 31, 2018. The...
-
Apr 6, 2018
Transaction broadens Cipher's Canadian dermatology portfolio with first and only prescription product for raised seborrheic keratoses (SKs) MISSISSAUGA, ON, April 6, 2018 /CNW/ - Cipher...
-
Mar 20, 2018
Cipher to Acquire Cardiome's Canadian Business Portfolio, Comprised of Four Commercial and Pipeline Assets Targeting Cardiovascular and Anti-Infective Indications for Upfront Consideration of...
-
Feb 28, 2018
90% increase in revenue and 214% increase in income from continuing operations for Q4 2017 Canadian launch of OZANEX™ in Jan 2018 Acquired Canadian rights to TRULANCE® in Feb 2018 MISSISSAUGA, ON,
-
Feb 28, 2018
A new differentiated treatment option for GI disorders Transaction broadens Cipher's Canadian portfolio providing entry into rapidly growing market where innovative treatments are needed...
-
Feb 9, 2018
Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q4 and full-year 2017 financial results conference call on Wednesday, February 28, 2018. Q4 AND...
-
Jan 9, 2018
Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has entered into an exclusive distribution and supply agreement with Italmex Pharma S.A. ("Italmex") under which Cipher has granted Italmex...
-
Jan 8, 2018
Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Canadian launch of OZANEX™ (ozenoxacin cream, 1%), a novel bactericidal topical antibiotic cream indicated for the treatment of impetigo...